Market Overview

AstraZeneca, Bristol-Myers Squibb, Announce Results from Phase IIa Study Assessing Safety and Tolerability of Dapagliflozin

Related AZN
Benzinga's Top Downgrades
AstraZeneca Falls More Than 5% Following Q4 Print
AstraZeneca's (AZN) CEO Pascal Soriot on Q4 2015 Results - Earnings Call Transcript (Seeking Alpha)

AstraZeneca (NYSE: AZN) and Bristol-Myers
Squibb  (NYSE: BMY) today announced results from a two-week
Phase IIa pilot study evaluating dapagliflozin added to insulin in 70
adult patients with sub-optimally controlled type 1 diabetes. Results
from this study showed that in patients treated with dapagliflozin, no
subjects discontinued due to lack of glycemic control, few genital and
urinary tract infections were reported and hypoglycemia was observed in
all treatment groups. In addition, mean daily blood glucose derived from
7-point glucose measurements trended downward in all treatment groups
through day seven and reductions in total daily insulin dosing at day
seven were observed with dapagliflozin. These findings will be presented
Sunday, June 23, in a late-breaking poster session at the 73rd

See full press release

Posted-In: News Guidance Management


Related Articles (AZN + BMY)

Get Benzinga's Newsletters